A Preliminary Report on the Use of Para-Amino Salicylic Acid in the Treatment of Pulmonary Tuberculosis

Sweany, Henry C.; Turner, Geoffrey; Lichtenstein, M. R.; Entin, Samson

doi:10.1378/chest.16.6.633

Cited by 8 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was not until the mid-1900s that the first anti-TB drug, streptomycin ( 1 ), was introduced . Its discovery was soon followed by resistance in bacterial strains found to be mainly due to a mutation in the rpsL gene. , Although p -amino salicylic acid ( 2 ) was developed before streptomycin, it was introduced a couple of years later, and just three years after its discovery, rapid development of resistance was noted. , Trials by the British Medical Research Council (BMRC) led to an axiom of tuberculous chemotherapy to never treat an active TB with a single agent. Indeed, when streptomycin and p -amino salicylic acid were used in combination, a reduction in occurrence of drug resistance was observed as compared to their use alone. , A few years later, in 1952, a new drug, isoniazid ( 3 ), was introduced which was known to be far better than other drugs owing to its effectiveness, safety, and inexpensiveness.…”

Section: Chronology Of Tuberculous Chemotherapy and Treatmentmentioning

confidence: 99%

“…80,81 Although p-amino salicylic acid (2) was developed before streptomycin, it was introduced a couple of years later, and just three years after its discovery, rapid development of resistance was noted. 82,83 Trials by the British Medical Research Council (BMRC) led to an axiom of tuberculous chemotherapy to never treat an active TB with a single agent. Indeed, when streptomycin and pamino salicylic acid were used in combination, a reduction in occurrence of drug resistance was observed as compared to their use alone.…”

Section: Chronology Of Tuberculous Chemotherapy and Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains

et al. 2021

View full text Add to dashboard Cite

Tuberculosis (TB) is a slow growing, potentially debilitating disease that has plagued humanity for centuries and has claimed numerous lives across the globe. Concerted efforts by researchers have culminated in the development of various strategies to combat this malady. This review aims to raise awareness of the rapidly increasing incidences of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis, highlighting the significant modifications that were introduced in the TB treatment regimen over the past decade. A description of the role of pathogen–host immune mechanisms together with strategies for prevention of the disease is discussed. The struggle to develop novel drug therapies has continued in an effort to reduce the treatment duration, improve patient compliance and outcomes, and circumvent TB resistance mechanisms. Herein, we give an overview of the extensive medicinal chemistry efforts made during the past decade toward the discovery of new chemotypes, which are potentially active against TB-resistant strains.

show abstract

Section: Chronology Of Tuberculous Chemotherapy and Treatmentmentioning

confidence: 99%

Section: Chronology Of Tuberculous Chemotherapy and Treatmentmentioning

confidence: 99%

Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Streptomycin targets bacterial protein synthesis, and mutations in the 16S ribosomal DNA ( rrs ) and the S12 ribosomal protein gene ( rpsL ) can cause resistance (Figure 1). Para-aminosalicylic acid (PAS) was widely introduced in 1946 (Lehmann, 1946) and reports of resistance appeared in 1949 (Sweany, 1949; Dunner et al, 1949). Resistance mutations map to genes involved in folate and salicylate metabolism (Mathys, V. et al, 2009).…”

Section: Tuberculosismentioning

confidence: 99%